When evaluating opportunities for development in indications with expression of the TAT, we identified several scenarios not exploited like Enfortumab vedotin, anti‐Nectin4, in cervical and lung cancer, Tisotumab vedotin, anti‐TF, in glioblastoma and pancreatic cancer, or Sacituzumab govitecan, anti‐TROP2, in cervical, pancreatic, gastric, thyroid and endometrial cancer. Here, TACSTD2 is linked to pancreatic neoplasm.